Schott Pharma stock: BofA lifts rating to Neutral

Published on 11/01/2026 at 12:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BofA upgraded Schott Pharma stock to Neutral from Underperform and set a EUR 27 price target. The move reflects its medium-term growth view.

BofA resets its Schott Pharma view

BofA upgraded the rating from Underperform to Neutral.
The bank set a EUR 27 price target and expects the company to meet its medium-term organic revenue growth target.

Schott Pharma, DE000A3ENQ51, Illustration mit AI erstellt.

Bank of America upgraded Schott Pharma from Underperform to Neutral on October 16, 2026, and set a EUR 27 price target. Markets Insider, citing TipRanks and TheFly, said the bank expects the company to meet its medium-term organic revenue growth target.

The rating change gives investors a more balanced view of the pharmaceutical packaging specialist after the earlier negative stance. The target remains a reference point for valuation rather than a guarantee of future performance.

Rating change meets market focus

Schott Pharma stock traded at 24.98 euros on Lang & Schwarz at 1:04 p.m. CEST on Saturday, October 31, 2026. The quote was supplied by the real-time market feed.

The company serves pharmaceutical manufacturers with glass packaging and delivery systems. For investors, the main issue is whether organic growth can support the medium-term outlook while valuation and analyst expectations adjust.

Markets Insider reported the BofA rating change and the EUR 27 target. Investors should distinguish the dated analyst action from later market pricing.

See the real-time quote of Schott Pharma stock for the latest trading information.